The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
JAK2V617F mutation for the early diagnosis of Ph− myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis
Open accessAbstract
Recent studies suggested that JAK2V617F mutation is frequent in patients with splanchnic vein thrombosis (SVT) but not in patients with other venous thromboembolic events (VTE). However, whether screening for the JAK2V617F mutation in VTE patients is justified remains unclear. Therefore, we performed a systematic review to assess the frequency of JAK2 mutation in VTE patients and the role of JAK2V617F mutation in the diagnosis of myeloproliferative neoplasms. MEDLINE and EMBASE databases were searched. Two reviewers independently performed study selection and extracted study characteristics. Pooled odds ratios of case-control studies and weighted mean proportion of the prevalence of JAK2V617F mutation of uncontrolled series were calculated. Twenty-four studies involving 3123 patients were included. Mean prevalence of JAK2 mutation was 32.7% (95% confidence interval, 25.5%-35.9%) in SVT patients. JAK2 mutation was associated with increased risk of SVT (odds ratio, 53.98; 95% confidence interval, 13.10-222.45). Mean prevalence of JAK2 mutation in other VTE patients was low (range, 0.88%-2.57%). Presence of JAK2V617F mutation in SVT patients was associated with a subsequent diagnosis of myeloproliferative neoplasm in many patients. JAK2 mutation is strongly associated with SVT, and routine screening of JAK2 mutation appears to be indicated in these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A meta-analysis reported a JAK2 mutationprevalenceof32.7%(95%CI25.5 e 35.9%)inpatients with AMVT compared with approximately 1% in patients with VTEinothersites, and found a strong association between JAK2 mutation and MVT (OR 53.9, 95% CI 13.1 e 222.5). 214”
In the citing paper
“A meta-analysis reported a JAK2 mutationprevalenceof32.7%(95%CI25.5 e 35.9%)inpatients with AMVT compared with approximately 1% in patients with VTEinothersites, and found a strong association between JAK2 mutation and MVT (OR 53.9, 95% CI 13.1 e 222.5). 214”
In the citing paper
“The JAK2 mutation is diagnostic of myeloproliferative diseases and appears to be linked to the development of AMVT.”
In the citing paper
“Moreover, 52% (95% CI 38 e 67%) of patients with MVT and JAK2 mutation were diagnosed with a myeloproliferative disease during follow up, with MVT being the first manifestation of the underlying condition. 214”
In the citing paper
“AMVT is a common first clinical manifestation in patients with newly diagnosed myeloproliferative diseases such as polycythemia vera or essential thrombocytosis.”
In the citing paper
“A meta-analysis reported a JAK2 mutationprevalenceof32.7%(95%CI25.5 e 35.9%)inpatients with AMVT compared with approximately 1% in patients with VTEinothersites, and found a strong association between JAK2 mutation and MVT (OR 53.9, 95% CI 13.1 e 222.5). 214”
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Investigating and dealing with publication and other biases in meta-analysis
Sterne, J. A. C., Egger, M., & Smith, G. D. (2001) · BMJ · doi:10.1136/bmj.323.7304.101 · Cited by 2,225
Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H., Barbui, T., Hanson, C., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083501 · Cited by 919
Campbell, P. J., Scott, L. M., Buck, G. A. N., Wheatley, K., East, C. L., Marsden, J. T., Duffy, A. M., Boyd, E. M., Bench, A. J., Scott, M. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67785-9 · Cited by 651
Polycythemia Vera: The Natural History of 1213 Patients Followed for 20 Years
Policitemia, G. I. S. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-9-199511010-00003 · Cited by 507
Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic)
McGinn, T. G. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1031981 · Cited by 482
Polycythemia vera: myths, mechanisms, and management
Spivak, J. L. (2002) · Blood · doi:10.1182/blood-2001-12-0349 · Cited by 458
Stefano, V. D., Zà, T., Rossi, E. G., Vannucchi, A. M., Ruggeri, M., Elli, E. M., Micò, M. C., Tieghi, A., Cacciola, R. R., Santoro, C., et al. (2008) · Haematologica · doi:10.3324/haematol.12053 · Cited by 366
Kiladjian, J., Cervantes, F., Leebeek, F. W. G., Marzac, C., Cassinat, B., Chevret, S., Cazals-Hatem, D. L., Plessier, A., García‐Pagán, J. C., Murad, S. D., et al. (2008) · Blood · doi:10.1182/blood-2007-11-125328 · Cited by 356
Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd–Chiari Syndrome
Patel, R., Lea, N. C., Heneghan, M. A., Westwood, N., Milojković, D., Thanigaikumar, M., Yallop, D., Arya, R., Pagliuca, A., Gäken, J. A., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.008 · Cited by 277
Primignani, M., Barosi, G., Bergamaschi, G., Gianelli, U., Fabris, F. M., Reati, R., Dell'era, A., Bucciarelli, P., & Mannucci, P. (2006) · Hepatology · doi:10.1002/hep.21435 · Cited by 272
Etiology of portal vein thrombosis in adults
Valla, D. C., Casadevall, N., Huisse, M., Tulliez, M., Grangé, J., Muller, O., Binda, T., Varet, B. R., RUEFF, B., & Benhamou, J. P. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90567-7 · Cited by 248
Stefano, V. D., Fiorini, A., Rossi, E., Zà, T., Farina, G., Chiusolo, P., Sica, S., & Leone, G. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02424.x · Cited by 220
Chaït, Y., Condat, B., Cazals-Hatem, D. L., Rufat, P., Atmani, S., Chaoui, D., Guilmin, F., Kiladjian, J., Plessier, A., Denninger, M. H., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05490.x · Cited by 171
JAK2(V617F): Prevalence in a large Chinese hospital population.
Xu, X., Zhang, Q., Luo, J., Xing, S., Li, Q.-S., Krantz, S., Fu, X.-Q., & Zhao, Z. (2007) · Blood · doi:10.1182/blood-2006-03-009472 · Cited by 169
The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis
Colaizzo, D., Amitrano, L., Tiscia, G. L., Scenna, G., Grandone, E., Guardascione, M. A., Brancaccio, V., & Margaglione, M. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02277.x · Cited by 168
Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome.
Smalberg, J. H., Murad, S. D., Braakman, E., Valk, P. J. M., Janssen, H. L. A., & Leebeek, F. W. G. (2006) · PubMed · Cited by 85
Complications of Injecting Dissolved Methylphenidate Tablets
Hahn, H. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300160046008 · Cited by 83
The case-control study. A practical review for the clinician.
Hayden, G. F., Kramer, M. S., & Horwitz, R. I. (1982) · PubMed · Cited by 73
Boissinot, M., Lippert, É., Girodon, F., Dobo, I., Fouassier, M., Masliah, C., Praloran, V., & Hermouet, S. (2006) · Blood · doi:10.1182/blood-2006-05-021527 · Cited by 69
JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis
Régina, S., Hérault, O., d’Altéroche, L., Binet, C., & Gruel, Y. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02384.x · Cited by 68
The JAK2V617F mutation and thrombosis
Austin, S. K., & Lambert, J. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07258.x · Cited by 65
Hayden, G. F. (1982) · JAMA · doi:10.1001/jama.1982.03320280046028 · Cited by 56
Colaizzo, D., Amitrano, L., Iannaccone, L., Vergura, P., Cappucci, F., Grandone, E., Guardascione, M. A., & Margaglione, M. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.048371 · Cited by 55
Pardanani, A. D., Lasho, T. L., Hussein, K., Schwager, S. M., Finke, C. M., Pruthi, R. K., & Tefferi, A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.4.457 · Cited by 53
Teofili, L., Stefano, V. D., Leone, G. G. M., Micalizzi, P., lovino, M. S., Alfano, G., & Bizzi, B. (1992) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648435 · Cited by 50
A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis
Colaizzo, D., Amitrano, L., Tiscia, G. L., Grandone, E., Guardascione, M. A., & Margaglione, M. (2007) · Blood · doi:10.1182/blood-2007-05-092502 · Cited by 48
Myeloproliferative Disease in the Pathogenesis and Survival of Budd-Chiari Syndrome.
Smalberg, J. H., Murad, S. D., Braakman, E., Valk, P. J. M., Kappers‐Klunne, M. C., Janssen, H. L. A., & Leebeek, F. W. G. (2006) · Blood · doi:10.1182/blood.v108.11.1480.1480 · Cited by 46
JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses.
McMahon, C., Abu-Elmagd, K., Bontempo, F., Kant, J., & Swerdlow, S. (2007) · American Journal of Clinical Pathology · doi:10.1309/ja1wd8jnvlgynqye · Cited by 44
The V617F mutation of JAK2 is very uncommon in patients with thrombosis
Remacha, A. F., Estivill, C., Sardà, M. P., Mateo, J., Souto, J. C., Canals, C., Nomdedeu, J. F., & Fontcuberta, J. (2007) · Haematologica · doi:10.3324/haematol.10358 · Cited by 39
Bergamaschi, G., Primignani, M., Barosi, G., Fabris, F. M., Villani, L., Reati, R., Dell’Era, A., & Mannucci, P. M. (2008) · Blood · doi:10.1182/blood-2008-02-137687 · Cited by 34
Pardanani, A. D., Lasho, T. L., Schwager, S. M., Finke, C. M., Hussein, K., Pruthi, R. K., & Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404710 · Cited by 33
GOULDING, C., Uttenthal, B. J., Foroni, L., Duke, V. M., Abdramane, T., Kottaridis, P. D., Hoffbrand, A. V., Patch, D., & McNamara, C. (2007) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2007.00973.x · Cited by 32
Ugo, V., Gal, G. L., Lecucq, L., Mottier, D., & Oger, E. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02811.x · Cited by 31
JAK2V617F Mutation in Patients with Portal Vein Thrombosis
Bayraktar, Y., Harmancı, Ö., Büyükaşık, Y., Shorbagi, A., Sungur, A. H., Akyerli, C. B., Gürgey, A., & Balkancı, F. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0225-y · Cited by 31
JAK2 V617F: implications for thrombosis in myeloproliferative diseases
Hexner, E. O. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282861d1b · Cited by 29
Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis
Xavier, S. G., Gadelha, T., Schaffel, R., Britto, L., Pimenta, G., Ribeiro, D. D., Sabino, A. D. P., Pires, V., Renault, I. Z., & Spector, N. (2008) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e328304e0a9 · Cited by 26
Occurrence of the JAK2 V617F mutation in the Budd–Chiari syndrome
Colaizzo, D., Amitrano, L., Tiscia, G. L., Iannaccone, L., Gallone, A., Grandone, E., Guardascione, M. A., & Margaglione, M. (2008) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e3283049662 · Cited by 24
Cassinat, B., Bonnin, N., Marzac, C., Crassard, I., & Bellucci, S. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-02-0081 · Cited by 24
Tiribelli, M., Colatutto, A., Marin, L., Barbina, G., Qualizza, U., Damiani, D., Toffoletti, E., Medeot, M., Candoni, A., Tonutti, E., et al. (2008) · American journal of hematology/oncology · doi:10.1002/ajh.21159 · Cited by 24
Janssen, H. L. A., & Leebeek, F. W. G. (2006) · Hepatology · doi:10.1002/hep.21489 · Cited by 24
Rossi, D., Cresta, S., Destro, T. R. D. S., Vendramin, C., Bocchetta, S., Paoli, L. D., Cerri, M., Lunghi, M., & Gaïdano, G. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06715.x · Cited by 19
The JAK2 V617F mutation in patients with cerebral venous thrombosis: A rebuttal
Rossi, E., Zà, T., Chiusolo, P., Leone, G. G. M., & Stefano, V. D. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-04-0205 · Cited by 16
High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis
Stefano, V. D., Fiorini, A., Rossi, E., Zà, T., Chiusolo, P., Sica, S., & Leone, G. G. M. (2007) · Hepatology · doi:10.1002/hep.21601 · Cited by 15
Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation
Colaizzo, D., Tiscia, G. L., Vergura, P., Chinni, E., Iannaccone, L., Antinolfi, I., Guardascione, M. A., Margaglione, M., & Grandone, E. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-09-0570 · Cited by 14
P’ng, S., Carnley, B., Baker, R. I., Kontorinis, N., & Cheng, W. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.12.046 · Cited by 13
JAK2V617F mutation is not associated with unexplained recurrent arterial and venous thrombosis
Sène, D., Elalamy, I., Ancri, A., & Cacoub, P. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2007.12.008 · Cited by 11
Garcés‐Eisele, J., González-Carrillo, M. L., Reyes‐Núñez, V., & Ruiz-Argüelles, G. J. (2008) · Hematology · doi:10.1179/102453308x316077 · Cited by 11
JAK2 V617F mutation is not involved in thromboembolism in IBD
Karimi, O., Crusius, B. J. A., Coucoutsi, C., Heijmans, R., Sambuelli, A. M., Peña, A. S., & Κoutroubakis, I. E. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20471 · Cited by 10
Janus kinase-2 mutation, cirrhosis and splanchnic vein thrombosis
Colaizzo, D., Amitrano, L., Guardascione, M. A., Balzano, A., & Margaglione, M. (2008) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3282f1cff7 · Cited by 10
Striking response to intrathecal liposomal cytarabine in a patient with meningeal myelomatosis
Colagrande, M., Ianni, M. D., Ciurnelli, R., Gallucci, M., Mariani, G., & Tabilio, A. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06712.x · Cited by 10
Endogenous Erythroid Colony Formation in Patients with Retinal Vein Occlusion
Héron, E., Marzac, C., Feldman-Billard, S., Girmens, J., Pâques, M., Delarue, R., Pietté, J. C., Casadevall, N., & Hermine, O. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.08.014 · Cited by 10
The JAK2 V617F mutation is not a cause of central retinal vein occlusion
Slachmuylder, V., Gala, J., Lambert, C., Detrait, M. Y., & Hermans, C. R. J. R. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-12-0729 · Cited by 4
Famularo, G., Minisola, G., & Simone, C. D. (2008) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2007.11.041 · Cited by 4
Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia
Palmisano, M., Grafone, T., Renzulli, M., Ottaviani, E., Testoni, N., Paolini, S., Papayannidis, C., Baccarani, M., & Martinelli, G. (2008) · Hematology · doi:10.1179/102453308x315753 · Cited by 3
Cited by
Sorted by citations
Epidemiology of venous thromboembolism
Heit, J. A. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.83 · Cited by 1,277
The epidemiology of venous thromboembolism
Heit, J. A., Spencer, F. A., & White, R. H. R. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1311-6 · Cited by 1,142
Editor's Choice – Management of the Diseases of Mesenteric Arteries and Veins
Björck, M., Koelemay, M., Acosta, S., Bastos Goncalves, F., Kölbel, T., Kolkman, J. J., Lees, T., Lefevre, J. H., Menyhei, G., Oderich, G., et al. (2017) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2017.01.010 · Cited by 658
Therapeutic strategies for thrombosis: new targets and approaches
Mackman, N., Bergmeier, W., Stouffer, G. A., & Weitz, J. I. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0061-0 · Cited by 413
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis
Smalberg, J. H., Arends, L. R., Valla, D. C., Kiladjian, J., Janssen, H. L. A., & Leebeek, F. W. G. (2012) · Blood · doi:10.1182/blood-2011-09-376517 · Cited by 374
Metadata
- Authors
- Dentali, F., Squizzato, A., Brivio, L., Appio, L., Campiotti, L., Crowther, M., Grandi, A. M., & Ageno, W.
- Affiliations
- University of Insubria (IT)
- McMaster University (CA)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-05-28
- Volume
- 113
- Issue
- 22
- Pages
- 5617-5623
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2000782581
- Cited by
- 176
- References
- 60
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 12 · 2019: 7 · 2018: 6 · 2017: 10 · 2016: 8 · 2015: 12 · 2014: 12 · 2013: 13 · 2012: 18
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- JAK2 V617F mutation, myeloproliferative neoplasms, venous thromboembolism, splanchnic vein thrombosis, mutation detection, early diagnosis, prevalence
- MeSH terms
- Algorithms, Female, Gene Frequency, Humans, Male, Myeloproliferative Disorders, Neoplasms, Phenylalanine, Philadelphia Chromosome, Biomarkers, Tumor, Valine, Case-Control Studies, Point Mutation, Amino Acid Substitution, Janus Kinase 2, Venous Thromboembolism, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
